Welcome!

News Feed Item

Global Protein Therapeutics Market Outlook 2018

NEW YORK, Jan. 20, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Protein Therapeutics Market Outlook 2018
http://www.reportlinker.com/p01974624/Global-Protein-Therapeutics-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Protein based therapies have found a prominent place in the biopharmaceutical industry since the launch of the human insulin product. They have become one of the most effective clinical methods to treat a wide spectrum of diseases ranging from cancer to metabolic disorders. The market holds tremendous potential for future growth and it is estimated that by the end of 2018, it may reach the mark of US$ 165 Billion as new products (especially monoclonal antibodies in the advanced clinical phase) may enter the sector.

According to our new research report, "Global Protein Therapeutics Market Outlook 2018", a large number of market players has been developing monoclonal antibodies (mAbs). Our research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments.

Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of the products' sales. However, our team of researchers has come up with an analysis that the future landscape of the market may find positive developments from Asian countries as huge patients' population and increasing disposable incomes may turn out to be a win-win condition for industry participants.

The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.

The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.

At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided alongwith its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Global Protein Therapeutics Market
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2018
3.2.1 Market Segmentation
4. Industry Performance
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2018
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2018
4.2.3 By Application
4.2.4 Key Geographical Markets

4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3 Insulin
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2018
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2018
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2018
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2018
4.6.3 Key Players and Drugs
4.6.4 Recent Developments

4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2018
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2018
4.8.3 Key Players and Drugs
4.8.4 Recent Developments
5. Advanced Phase Drugs Analysis
6. Emerging Market Trends
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
7. Key Players
7.1 Johnson & Johnson
7.2 Biogen Idec Inc.
7.3 Eli Lilly & Company
7.4 Sanofi-Aventis
7.5 Merck Serono S.A.
7.6 Roche Group
7.7 Amgen Inc.
7.8 Pfizer
7.9 Abbott Laboratories
7.10 Novo Nordisk

List of Figures:

Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2012
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2012-2018
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2012
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2018
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2012
Figure 4-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2011 & 2012
Figure 4-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2011 & 2012
Figure 4-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2011 & 2012
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-9: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-10: Global - Number of Patients on Dialysis (Million), 2010-2012
Figure 4-11: Global - Breakup of Patients on Dialysis by Region (%), 2012
Figure 4-12: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-13: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-14: Global - Share of US in EPO Market (2012)
Figure 4-15: Global - Insulin Market (Billion US$), 2012-2018

Figure 4-16: Global - Number of Diabetic Patients (Million), 2012 & 2030
Figure 4-17: China - Insulin Market (Billion US$), 2012-2018
Figure 4-18: US - Insulin Market (Billion US$), 2012-2018
Figure 4-19: Japan - Insulin Market (Billion US$), 2012-2018
Figure 4-20: Global - Share of Key Players in Insulin Market (2012)
Figure 4-21: Global - Share of Products in Insulin Market (2012)
Figure 4-22: Global - Interferon Market (Billion US$), 2012-2018
Figure 4-23: Global - Share of Alpha and Beta Products in Interferon Market (2012)
Figure 4-24: Global - Interferon Alpha Market (Billion US$), 2010-2012
Figure 4-25: Global - Interferon Beta Market (Billion US$), 2010-2012
Figure 4-26: US - Interferon Market (Billion US$), 2010-2012
Figure 4-27: Japan - Interferon Market (Million US$), 2010-2012
Figure 4-28: Global - Human Growth Hormone Market (Billion US$), 2012-2018
Figure 4-29: Global - Share of Key Players in Human Growth Hormone Market (2012)
Figure 4-30: Global - Blood Clotting Factor Market (Billion US$), 2012-2018
Figure 4-31: Global - Share of Blood Clotting Factor Market by Segment (2012)
Figure 4-32: Global - Share of Key Players in Blood Clotting Factor Market (2012)
Figure 4-33: Global - Follicle Stimulating Hormone Market (Billion US$), 2012-2018
Figure 4-34: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2018

List of Tables:

Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2010-2012
Table 4-2: US - Sales of Key EPO Products (Billion US$), 2010-2012
Table 4-3: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2010-2012
Table 4-4: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2010-2012
Table 4-5: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2010-2012
Table 4-6: China - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-7: US - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-8: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030
Table 4-9: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2010-2012
Table 4-10: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2010-2012
Table 4-11: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2010-2012
Table 4-12: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2010-2012
Table 4-13: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2010-2012
Table 4-14: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2012
Table 5-1: Advanced Phase Protein Therapeutics
Table 7-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 7-2: Biogen Idec - Key Products in Protein Therapeutics
Table 7-3: Eli Lilly - Key Products in Protein Therapeutics
Table 7-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 7-5: Merck Serono - Key Products in Protein Therapeutics
Table 7-6: Roche - Key Products in Protein Therapeutics
Table 7-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 7-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 7-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 7-10: Novo Nordisk - Key Products in Protein Therapeutics

To order this report: Global Protein Therapeutics Market Outlook 2018
http://www.reportlinker.com/p01974624/Global-Protein-Therapeutics-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, discussed how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a practic...
Interoute has announced the integration of its Global Cloud Infrastructure platform with Rancher Labs’ container management platform, Rancher. This approach enables enterprises to accelerate their digital transformation and infrastructure investments. Matthew Finnie, Interoute CTO commented “Enterprises developing and building apps in the cloud and those on a path to Digital Transformation need Digital ICT Infrastructure that allows them to build, test and deploy faster than ever before. The int...
In his General Session at 17th Cloud Expo, Bruce Swann, Senior Product Marketing Manager for Adobe Campaign, explored the key ingredients of cross-channel marketing in a digital world. Learn how the Adobe Marketing Cloud can help marketers embrace opportunities for personalized, relevant and real-time customer engagement across offline (direct mail, point of sale, call center) and digital (email, website, SMS, mobile apps, social networks, connected objects).
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
"My role is working with customers, helping them go through this digital transformation. I spend a lot of time talking to banks, big industries, manufacturers working through how they are integrating and transforming their IT platforms and moving them forward," explained William Morrish, General Manager Product Sales at Interoute, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
SYS-CON Events announced today that Ocean9will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Ocean9 provides cloud services for Backup, Disaster Recovery (DRaaS) and instant Innovation, and redefines enterprise infrastructure with its cloud native subscription offerings for mission critical SAP workloads.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, will provide a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services ...
Imagine having the ability to leverage all of your current technology and to be able to compose it into one resource pool. Now imagine, as your business grows, not having to deploy a complete new appliance to scale your infrastructure. Also imagine a true multi-cloud capability that allows live migration without any modification between cloud environments regardless of whether that cloud is your private cloud or your public AWS, Azure or Google instance. Now think of a world that is not locked i...
SYS-CON Events announced today that Auditwerx will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Auditwerx specializes in SOC 1, SOC 2, and SOC 3 attestation services throughout the U.S. and Canada. As a division of Carr, Riggs & Ingram (CRI), one of the top 20 largest CPA firms nationally, you can expect the resources, skills, and experience of a much larger firm combined with the accessibility and atten...